The evidence leans negative1 supporting, 4 against, 0 worth knowing
Supporting
revenue grew 15% year on year in the quarter ending 2026-06-30
Against
trading 15% below its 200-day average
down 58% over twelve months
1 of the scans it matches has historically underperformed the market
net margin has narrowed from 15.7% to 6.5% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close back above 212, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working1
Revenue +14.8% year on year, Rs 71 cr to Rs 81 cr.
+14.8%Rs 71 crRs 81 cr
Needs watching3
Profit grew slower than revenue, -24.3% against +14.8%.
-24.3%+14.8%
Net profit -24.3% year on year, Rs 7 cr to Rs 5 cr.
-24.3%Rs 7 crRs 5 cr
Net margin moved from 9.8% to 6.5%.
9.8%6.5%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
3 of 47 matched on 2026-08-21
GENESYS matches 3 of the 47 scans today, across 2 different kinds of evidence.
GENESYS trades at 24× trailing earnings, below its median of 29× over this window — 16% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Management filings were typically -0.01pt vs the market over the next 5 sessions (n=1,988) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 15% against the same quarter a year earlier
Going against it
profit dropped 24% year on year
net margin narrowed from 12.2% to 6.5%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
81
8
5
1.26
6.5%
Q4 FY26
2026-03-31 · consolidated
104
17
13
3.04
12.2%
Q3 FY26
2025-12-31 · consolidated
76
2
1
0.25
1.4%
Q2 FY26
2025-09-30 · consolidated
77
15
12
2.89
15.7%
Q1 FY26
2025-06-30 · consolidated
71
12
7
1.75
9.8%
Q4 FY25
2025-03-31 · consolidated
94
32
19
4.77
20.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-15.0%
Versus 200-day average-15.4%
Below 52-week high-57.3%
Above 52-week low+33.6%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)41.1
Higher closes in last 53 of 5
Six-month return−13.44%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.